Horizon Therapeutics Public Limited Company (HZNP) : Free Stock Analysis ReportĪCADIA Pharmaceuticals Inc. (AMGN) : Free Stock Analysis ReportĪDC Therapeutics SA (ADCT) : Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. ![]() ![]() Year to date, shares of ACAD have rallied 93.5%.ĪCAD beat estimates in two of the trailing four quarters, missing the mark on other two occasions, delivering an average negative earnings surprise of 2.75%. The estimate for Acadia Pharmaceuticals’ 2024 earnings per share is pegged at 47 cents. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 58 cents to 31 cents. Year to date, shares of ADCT have lost 63%.ĪDCT beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 10.70%. During the same period, the estimate for ADC Therapeutics’ 2024 loss per share narrowed from $2.72 to $2.45. In the past 90 days, the Zacks Consensus Estimate for ADC Therapeutics’ 2023 loss per share has widened from $2.58 to $2.61. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Horizon currently has a Zacks Rank #3 (Hold).Ī couple of better-ranked stocks in the same industry are ADC Therapeutics ADCT and Acadia Pharmaceuticals ACAD, each carrying a Zacks Rank #2 (Buy) at present. Non-Employee Director Compensation Policy. Horizon Therapeutics Public Limited Company price-consensus-chart | Horizon Therapeutics Public Limited Company Quote Zacks Rank and Stocks to Consider Horizon Therapeutics Public Limited Company. Horizon Therapeutics Public Limited Company Price and Consensus In May 2023, the Federal Trade Commission (FTC) filed a lawsuit in Federal Court to halt Amgen’s $28 billion acquisition of Horizon. The Company is a public limited company for the purposes of Part 17 of the Companies Act 2014 (the. The name of the Company is: Horizon Therapeutics public limited company. We would like to remind the investors that Horizon is set to be acquired by biotech giant Amgen AMGN for $116.5 per share in cash or $27.8 billion. HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY. The total patient population was randomized into three parallel arms, receiving either daxdilimab given subcutaneously 200 mg every four weeks, 200 mg every 12 weeks or placebo every four weeks. Additional endpoints of the study included other measures of lupus disease activity and reduction in OGC. The phase II study evaluating daxdilimab for the treatment of SLE enrolled 214 patients with moderate-to-severely active SLE. ![]() Additionally, HZNP is also planning to investigate daxdilimab in treating dermatomyositis or anti-synthetase inflammatory myositis. The company is evaluating daxdilimab for several other indications, including alopecia areata, discoid lupus erythematosus and lupus nephritis. Horizon’s investigational candidate, daxdilimab, is an anti-ILT7 human monoclonal antibody that depletes certain dendritic cells potentially stopping inflammation of those cells from damaging tissue.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |